# Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

> **NCT06216392** · PHASE3 · UNKNOWN · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 450 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** GR1802 injection
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT06216392
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2025-06
- **Final completion:** 2026-01
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06216392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06216392, "Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06216392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*